196 related articles for article (PubMed ID: 30946704)
1. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder.
Hobart M; Zhang P; Skuban A; Brewer C; Hefting N; Sanchez R; McQuade RD
J Clin Psychopharmacol; 2019; 39(3):203-209. PubMed ID: 30946704
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study.
Hobart M; Skuban A; Zhang P; Josiassen MK; Hefting N; Augustine C; Brewer C; Sanchez R; McQuade RD
Curr Med Res Opin; 2018 Apr; 34(4):633-642. PubMed ID: 29343128
[TBL] [Abstract][Full Text] [Related]
3. Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study.
Fava M; Ménard F; Davidsen CK; Baker RA
J Clin Psychiatry; 2016 Dec; 77(12):1695-1701. PubMed ID: 27379823
[TBL] [Abstract][Full Text] [Related]
4. Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis.
Kishi T; Sakuma K; Nomura I; Matsuda Y; Mishima K; Iwata N
Int J Neuropsychopharmacol; 2019 Nov; 22(11):698-709. PubMed ID: 31350882
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
[TBL] [Abstract][Full Text] [Related]
6. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia.
Forbes A; Hobart M; Ouyang J; Shi L; Pfister S; Hakala M
Int J Neuropsychopharmacol; 2018 May; 21(5):433-441. PubMed ID: 29415258
[TBL] [Abstract][Full Text] [Related]
7. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study: Brexpiprazole d'appoint pour l'engagement dans la vie des patients souffrant de trouble dépressif majeur: une étude interventionnelle canadienne ouverte de phase 4.
Therrien F; Ward C; Chokka P; Habert J; Ismail Z; McIntyre RS; MacKenzie EM
Can J Psychiatry; 2024 Jul; 69(7):513-523. PubMed ID: 38425284
[TBL] [Abstract][Full Text] [Related]
9. A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder.
Bauer M; Hefting N; Lindsten A; Josiassen MK; Hobart M
Acta Neuropsychiatr; 2019 Feb; 31(1):27-35. PubMed ID: 30223911
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study.
Lepola U; Hefting N; Zhang D; Hobart M
Int J Geriatr Psychiatry; 2018 Oct; 33(10):1403-1410. PubMed ID: 30039634
[TBL] [Abstract][Full Text] [Related]
11. Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole: Pooled Analysis of Phase 3 Clinical Studies.
Newcomer JW; Eriksson H; Zhang P; Meehan SR; Weiss C
J Clin Psychiatry; 2019 Oct; 80(6):. PubMed ID: 31577867
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
Thase ME; Youakim JM; Skuban A; Hobart M; Augustine C; Zhang P; McQuade RD; Carson WH; Nyilas M; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
[TBL] [Abstract][Full Text] [Related]
13. Effects of Adjunctive Brexpiprazole on Sleep Disturbances in Patients With Major Depressive Disorder: An Open-Label, Flexible-Dose, Exploratory Study.
Krystal AD; Mittoux A; Meisels P; Baker RA
Prim Care Companion CNS Disord; 2016 Sep; 18(5):. PubMed ID: 27835722
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study.
Davis LL; Ota A; Perry P; Tsuneyoshi K; Weiller E; Baker RA
Brain Behav; 2016 Oct; 6(10):e00520. PubMed ID: 27781135
[TBL] [Abstract][Full Text] [Related]
15. Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
Fava M; Okame T; Matsushima Y; Perry P; Weiller E; Baker RA
Int J Neuropsychopharmacol; 2017 Jan; 20(1):22-30. PubMed ID: 27784751
[TBL] [Abstract][Full Text] [Related]
16. Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania.
Vieta E; Sachs G; Chang D; Hellsten J; Brewer C; Peters-Strickland T; Hefting N
J Psychopharmacol; 2021 Aug; 35(8):971-982. PubMed ID: 33691517
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
18. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials.
McIntyre RS; Weiller E; Zhang P; Weiss C
J Affect Disord; 2016 Sep; 201():116-23. PubMed ID: 27208498
[TBL] [Abstract][Full Text] [Related]
19. Effect of Brexpiprazole on Prolactin and Sexual Functioning: An Analysis of Short- and Long-Term Study Data in Major Depressive Disorder.
Clayton AH; Ivkovic J; Chen D; George V; Hobart M
J Clin Psychopharmacol; 2020; 40(6):560-567. PubMed ID: 33136923
[TBL] [Abstract][Full Text] [Related]
20. A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder.
Hobart M; Skuban A; Zhang P; Augustine C; Brewer C; Hefting N; Sanchez R; McQuade RD
J Clin Psychiatry; 2018 May; 79(4):. PubMed ID: 29873953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
